This is a past event. Registration is closed. View other UK Department for Business and Trade events.
中文
English
It is estimated that there are over 7,000 rare diseases, with new conditions continually being identified as research advances. Rare diseases can be both life-limiting and life-threatening, and disproportionately affect children. It is crucial for international countries to work hand in hand for sharing, learning and collaboration to jointly meet rare disease challenges in research, access to medicine and patient care.
On 29th February, International Rare Disease Day, the UK Department for Business and Trade (DBT) and the Chinese Organization for Rare Disorders (CORD) will co-host the "Rare Disease Symposium - Working Together for the Future". The symposium aims to bring together policy makers, clinicians, researchers and innovative companies to achieve international exchanges between China and the UK on issues ranging from national policies to technological innovations, screening and diagnostics to coordinated care, and research trends to clinical excellence. The event will also build a platform for long-term action and international cooperation in education and training, scientific research, clinical services and technological innovation, and promote and strengthen mutual understanding and in-depth cooperation between China and the UK in the field of rare diseases.
Click the 'Register' button to sign up for the event and participate online or offline.
Time: Feb 29th 2024
Venue: Jeurong Hotel Shanghai (No. 80, Minhong Road Number 80, Minhang, Shanghai)
You may use 'Register' button above to register for the event. You can choose to participate online or in person. Due to the limited seats at the event venue, offline attendees will receive a ticket confirmation email.
Agenda
14
00
-
14
05
Moderator’s Opening and Guests Introduction
Vicky ZHANG, Head of Pharma, Department for Business and Trade, British Embassy Beijing
14
05
-
14
10
Opening Remark 1
Rufang HUANG, Founder & Director-General of CORD, Co-founder & Secretary-General of Hope for Rare Foundation
14
10
-
14
15
Opening Remark 2
Rahul AGARWAL, Counsellor for Healthcare & Life Sciences, Department for Business and Trade, British Embassy Beijing
14
15
-
14
30
Keynote Speech 1 - China Rare Disease Policy Development Overview and Looking Ahead
Chunlin JIN, Director-General of Shanghai Health Development Research Centre
14
30
-
14
45
Keynote Speech 2 - The UK Government Approach to Tackling Rare Diseases
Tom JACKSON, LVO, Counsellor, Health Policy, Foreign, Commonwealth & Development Office,
British Embassy Beijing
14
45
-
15
00
Presentation 1 - Opportunities and Challenges in Introducing Rare Disease Medications in China
Maggie CHEN, Head of Strategy & Portfolio Management, GSK China
15
00
-
15
15
Presentation 2 - Nanopore Sequencing in Clinical Genomics
Lin JIN, Associate Director, Regional Marketing, APAC, Oxford Nanopore Technology
15
15
-
15
35
15
35
-
15
50
Presentation 3 - Innovation and Technology Development of Rare Disease Sector in China
Yugang LIU, Global Partner & Head of Great China, Simon-Kucher & Partners
15
50
-
16
05
Presentation 4 - China’s Rare Disease Screening, Diagnosis and Treatment
Yi WANG, Head of Children's Hospital of Fudan University
16
05
-
16
20
Presentation 5 - Rare Disease – A Children’s Hospital Perspective (Diagnosis, Care and Research)
Dr Sophia VARADKAR, Deputy Medical Director, Acting Trust Medical Director and Consultant Paediatric Neurologist at GOSH
16
20
-
16
30
Q&A
Dr Sophia VARADKAR, Deputy Medical Director, Acting Trust Medical Director and Consultant Paediatric Neurologist at GOSH
Yi WANG, Head of Children's Hospital of Fudan University
16
30
-
17
55
Panel Discussion UK-China Partnership in Tackling Rare Disease Challenges Globally
Moderator：
Linguo, LI, Senior Researcher, Public Policy Research Centre of Rare Diseases, CORD
Panelists:
- Michael BRAUNAGEL, Managing Director, Actigen
- Xiaoxia HU, General Manager of External Affairs, Keyuan Xinhai (Beijing) Medical Products Trade Co., Ltd
- Deborah McGREGOR, Specialist, Scottish Development International
- Shawn XIANG, CEO, RareStone Group
- Jiahao HU, Head of Drug Evaluation, Health Policy Research Department, Shanghai Health Development Research Centre
17
55
-
18
00
Closing Remark
Rahul Agarwal, Counsellor for Healthcare & Life Sciences, Department for Business and Trade, British Embassy Beijing
18
00
-
18
15
18
15
-
20
00
